India, Nov. 13 -- Bolt Biotherapeutics, Inc. (BOLT) reported third-quarter 2026 financial results and outlined plans to advance its newly acquired inflammatory disease pipeline following the completion of its acquisition of Prana Therapies.
Company Profile
Bolt Biotherapeutics is a clinical-stage biotechnology company developing half-life-extended multispecific antibodies through the proprietary INSPIRE platform. Its lead candidate, PRA-216, is an IL-4Ra/TSLP bispecific antibody being developed for inflammatory conditions. The pipeline also includes BDC-4182, a Claudin 18.2-targeting Boltbody ISAC.
Third-Quarter 2026 Financial Results
Collaboration revenue was zero for the third quarter ended September 30, 2026, compared to $2.2 million...